News

All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said. Participants had received more than five previous lines of therapy for their cancer. CLR 131 is a phospholipid-drug conjugate (PDC) being developed for the treatment of…

Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in  multiple myeloma patients, a new study suggests. These symptoms can be common in patients, as hematopoietic stem cell transplant (HSCT) is preceded by a heavy dose of chemotherapy. Published in the journal Support Care…

A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of myeloma cells called B-cell maturation antigen (BCMA). Researchers were able to demonstrate that P-BCMA-101…

The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma. “Multiple myeloma is one of the most common forms of blood cancer in…

Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two factors that drive disease in patients with relapsed or refractory multiple myeloma. Researchers believe that having two targets might be more efficient in fighting the…

The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to continue evaluating its safety and effectiveness, and to determine a dose for a Phase 2 trial. Bluebird bio and Celgene developed the CAR T-cell therapy for patients with relapsed or…

The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first patient, Oncolytics Biotech recently announced. Reolysin is a proprietary formulation of the human reovirus that replicates inside cancer cells, leading to their death. By…

Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at the request of the U.S. Food and Drug Administration (FDA). Unexplained deaths in trials of Keytruda-based combinations prompted the FDA to halt other studies of immune…

Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at the Annual Meeting of the Society of Hematologic Oncology (SOHO) in Houston, Texas. The presentation was based on data from an ongoing Phase 2…

The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy to be used in combination with an anti-tumor antibody for the treatment of relapsed or refractory multiple myeloma. IND status will allow the company to…